Importantly, this distinction was maintained at the carcinoma stage where BRAF‐mutant CMS4 tumors showed higher levels of TGFβ‐induced target genes compared to BRAF‐mutated CMS1 tumors and vice versa genes reduced upon TGFβ treatment displayed lower expression in BRAF‐mutant CMS4 CRCs compared to CMS1 CRCs (Figs 5I and EV5C). The gene discussed is TGFB1; the disease is carcinoma.